** Shares of Arcellx up about 2.5% at $92 in afternoon trading
** Brokerage Guggenheim raises ACLX's PT to $105 from $77, maintains "buy" rating
** Brokerage continues to see an opportunity for co's lead product, anito-cel, to be the best therapy of its kind to treat a type of blood cancer called multiple myeloma
** Anito-cel is a CAR-T therapy, which uses modified T-cells of patients to fight cancer, and is being tested for multiple myeloma that relapses or stops responding to the treatment
** ACLX plans to present initial data from a mid-stage trial for anito-cel in December
** Brokerage says investors are expecting the initial data to show better efficacy for anito-cel compared to Johnson & Johnson - Legend Biotech's Carvykti
** Stock up ~66% YTD, including session's gains
(Reporting by Sruthi Narasimha Chari in Bengaluru)
((Sruthinarasimha.chari@thomsonreuters.com))
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。